Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy Jnl of Viral Hepatitis Sept 2008 T.-M.Scherzer 1 , K.
Reddy 2 , F.
Wrba 3 , H.
Hofer 1 , K.
Staufer 1 , P.
Steindl-Munda 1 , A.
Gangl 1 and P.
Ferenci 1 1 Department of Internal Medicine III, Division of Gastroenterology and...
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of hi 'An additional 0.3 log10 reduction in viral load was seen as early as hour 72 for the higher dose compared to the lower dose of peginterferon alfa-2a, at either dose of ribavirin.'........'Results of multiple logistic regression models...
High relapse rate seen at week 72 for patients treated with R1626 combination therapy Paul Pockros, M.D.1, David Nelson, M.D.
2, Eliot Godofsky, M.D.
3, Maribel Rodriguez-Torres, M.D.
4, Gregory T.
Everson, M.D., Ph.D.
5, Michael W.
Fried, M.D.
6, Reem Ghalib, M.D.
7, Stephen Harrison, M.D.
8, Lisa Nyberg...
Telaprevir Presentations at the 59th AASLD Meeting to Feature SVR Data CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept.24, 2008 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that key data on sustained viral response (SVR) rates in both treatment-naive and treatment-failure genotype 1 hepatitis...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting - Results of Phase 1 clinical studies support advancement to Phase 2 - BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227)...
Vertex Pharmaceuticals Announces Correction to Abstract Data Published in October 2008 Supplement to Hepatolog (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today provided a correction to AASLD abstract 1854 published in the October 2008 supplement of the journal Hepatology.The title of the abstract is 'Phase 2 Study of...
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepati BILN-2061, a specific and potent peptidomimetic inhibitor of the HCV NS3 protease, has recently been shown to markedly lower serum hepatitis C virus (HCV)-RNA levels in patients chronically infected with HCV genotype 1 in three 2-day proof...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting - Results of Phase 1 clinical studies support advancement to Phase 2 - BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227)...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting - Results of Phase 1 clinical studies support advancement to Phase 2 - - Results of in-vitro study of ITMN-191 with Roche polymerase inhibitors - BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting - Results of Phase 1 clinical studies support advancement to Phase 2 - - Results of in-vitro study of ITMN-191 with Roche polymerase inhibitors - BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN - News)...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting - Results of Phase 1 clinical studies support advancement to Phase 2 - BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227)...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227) accepted for presentation at the 59th Annual Meeting of the...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227) accepted for presentation at the 59th Annual Meeting of the...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227) accepted for presentation at the 59th Annual Meeting of the...
Vertex Pharmaceuticals Announces Correction to Abstract Data Published in October 2008 Supplement to Hepatolog source: Business Wire Vertex Pharmaceuticals Incorporated today provided a correction to AASLD abstract 1854 published in the October 2008 supplement of the journal Hepatology.The title of the abstract is 'Phase 2 Study of Telaprevir...
Vertex Pharmaceuticals Announces Correction to Abstract Data Published in October 2008 Supplement to Hepatolog CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - News) today provided a correction to AASLD abstract 1854 published in the October 2008 supplement of the journal Hepatology.The title of the abstract...
Vertex Pharmaceuticals Announces Correction to Abstract Data Published in October 2008 Supplement to Hepatolog Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today provided a correction to AASLD abstract 1854 published in the October 2008 supplement of the journal Hepatology.The title of the abstract is 'Phase 2 Study of Telaprevir...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting - Results of Phase 1 clinical studies support advancement to Phase 2 - BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227)...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting - Results of Phase 1 clinical studies support advancement to Phase 2 - BRISBANE, Calif., September 24, 2008 /PRNewswire-FirstCall/ -- InterMune, Inc.today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting - Results of Phase 1 clinical studies support advancement to Phase 2 - - Results of in-vitro study of ITMN-191 with Roche polymerase inhibitors - BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227) accepted for presentation at the 59th Annual Meeting of the...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, (News) Inc.
today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227) accepted for presentation at the 59th Annual Meeting of the American...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN - News) today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227) accepted for presentation at the 59th Annual Meeting of...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting BRISBANE, Calif., Sept.24 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227) accepted for presentation at the 59th Annual Meeting of the...
TopAbstracts in Hepatitis C 09/16/2008 TopAbstracts in Hepatitis C are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.Over 2000 peer-reviewed...
